Switching from Dulaglutide to Semaglutide: Dose Conversion & Timeline

Why Switch from Dulaglutide to Semaglutide?

Common clinical reasons for switching include:

• Efficacy: Seeking greater weight loss efficacy (14.9% vs 4.5%)
• Tolerability: Side effects on Dulaglutide that may differ with Semaglutide's distinct mechanism or formulation
• Insurance/cost: Formulary changes or coverage shifts favoring Semaglutide
• Mechanism upgrade: Mechanism difference: Semaglutide has higher receptor binding affinity and longer half-life (168h vs Dulaglutide's 90h) — explaining the larger weight loss effect

Dose Equivalence Table

There are no formally established dose equivalence conversions between most GLP-1 medications — each drug has its own dose-response curve and receptor binding profile. The general approach is to restart at the lowest titration dose of the new agent regardless of dose achieved on the prior agent.

Washout Period

No washout period required for weekly-to-weekly GLP-1 transition. The last dose of the previous drug can be substituted directly with the first dose of the new drug at the starting (titration) dose.

Dulaglutide has a half-life of approximately 90 hours. Semaglutide has a half-life of approximately 168 hours. These pharmacokinetic differences influence the transition protocol but rarely require a true drug-free washout period for GLP-1 class switches.

What to Expect: First 4 Weeks on Semaglutide

Patients switching to a new GLP-1 agent often experience a re-emergence of GI side effects (nausea, diarrhea, constipation) during the re-titration period, similar to what occurred when starting the first medication. This is normal and expected — the body is adapting to a new receptor agonist profile.

• Week 1–2: May experience mild nausea, especially if Semaglutide has a higher receptor affinity at baseline than Dulaglutide
• Week 2–4: GI symptoms typically stabilize; weight loss progress may briefly stall during re-titration
• Week 4+: Begin first dose escalation if dose is well tolerated
• Week 12–24: Expect to see meaningful efficacy data from the new agent

Monitoring After Switching

• Schedule a follow-up at 4–8 weeks post-switch to assess tolerability and early efficacy
• Monitor weight, blood glucose (if diabetic), and GI symptom pattern
• Ensure adequate hydration throughout re-titration period
• Report any unexpected or severe adverse events promptly

Drug Comparison: Dulaglutide vs Semaglutide

For a full comparison, see our Dulaglutide vs Semaglutide comparison page.

AWARD-11 Trial Data: How Dulaglutide Performs

The AWARD-11 trial — a phase 3, randomized, double-blind study published in Diabetes Care (2021) — tested dulaglutide at its higher approved doses (3.0 mg and 4.5 mg) against the standard 1.5 mg in 1,842 patients with type 2 diabetes on metformin. At 36 weeks, dulaglutide 4.5 mg reduced HbA1c by −1.87% versus −1.53% for 1.5 mg — a modest but statistically significant improvement. The odds of reaching HbA1c < 7.0% were approximately twice as high at the higher dose (OR 2.2).

For weight loss — the metric most relevant to switching decisions — results were dose-dependent but modest overall. At 52 weeks: dulaglutide 1.5 mg produced −3.1 kg, 3.0 mg produced −4.0 kg, and 4.5 mg produced approximately −5.0 kg. These numbers stand in stark contrast to semaglutide 2.4 mg's −15.3 kg achieved in STEP 1 — an approximately 10 kg absolute gap at their respective weight-management doses. An indirect treatment comparison (Diabetes, Obesity & Metabolism, 2021) confirmed that even semaglutide 1.0 mg (the standard diabetes dose) produced significantly greater weight loss than dulaglutide at any approved dose (ETD −1.95 to −2.65 kg).

The clinical implication: a patient maintained on maximum-dose dulaglutide 4.5 mg who has lost approximately 3–5 kg may stand to gain a further 10+ kg of weight reduction by switching to semaglutide 2.4 mg — a clinically significant gap that rivals the benefit of starting pharmacotherapy in the first place.

STEP Trial Data: How Semaglutide Performs

The STEP program established semaglutide 2.4 mg (Wegovy) as the most effective weekly GLP-1 agent currently available for weight management. In STEP 1 (N = 1,961 adults without T2D, 68 weeks), mean body weight fell −14.9% with semaglutide versus −2.4% with placebo. Remarkably, 86.4% of semaglutide participants achieved ≥ 5% weight loss, 69.1% achieved ≥ 10%, and 50.5% achieved ≥ 15% — thresholds essentially unattainable with dulaglutide at any approved dose.

For patients switching from dulaglutide who have type 2 diabetes, STEP 2 (N = 1,210 adults with overweight/obesity and T2D) showed mean weight loss of −9.6% with semaglutide 2.4 mg versus −3.4% with placebo at 68 weeks — still substantially greater than dulaglutide's AWARD-11 outcomes, though lower than in the non-diabetic cohort. HbA1c fell by approximately 1.6% with semaglutide 2.4 mg in T2D patients.

STEP 4 is directly relevant to the switching decision: participants who completed a 20-week run-in on semaglutide and then switched to placebo regained 6.9% body weight in the following 48 weeks. This finding works in both directions — a patient switching from dulaglutide to semaglutide can expect a new weight-loss phase, while any gap in therapy risks rebound. Across STEP 1–5, 69–79% of participants achieved ≥ 10% weight loss and 51–64% achieved ≥ 15% — consistently exceeding dulaglutide benchmarks.

The Head-to-Head Trial: SUSTAIN 7

SUSTAIN 7 (Pratley et al., Lancet Diabetes & Endocrinology, 2018) is the only large prospective head-to-head trial directly comparing semaglutide against dulaglutide. It enrolled 1,201 adults with T2D inadequately controlled on metformin and compared: semaglutide 0.5 mg vs dulaglutide 0.75 mg (low-dose arm), and semaglutide 1.0 mg vs dulaglutide 1.5 mg (high-dose arm) — both administered once weekly subcutaneously for 40 weeks.

HbA1c results: From a mean baseline of 8.2%, semaglutide reduced HbA1c by −1.8% versus −1.4% for dulaglutide 1.5 mg (ETD −0.41%, P < 0.0001 at the high-dose comparison). More patients on semaglutide achieved HbA1c < 7.0%: 79% vs 67% at the high-dose comparison. A 0.4 percentage-point advantage between two active agents is clinically meaningful — by UKPDS modelling, each 1% HbA1c reduction corresponds to approximately 21% lower diabetes-related mortality risk.

Weight loss results: From a mean baseline of 95.2 kg, semaglutide 1.0 mg produced −6.5 kg versus −3.0 kg with dulaglutide 1.5 mg (ETD −3.55 kg, 95% CI −4.32 to −2.78; P < 0.0001) — more than double the weight loss. A post-hoc BMJ Open subgroup analysis confirmed semaglutide's advantage was consistent across all patient subgroups, with the weight gap widening to approximately −4.1 kg in patients with BMI ≥ 35 kg/m². Adverse event profiles were described as "similar" between agents — GI disorders affected 44% (semaglutide 1.0 mg) vs 48% (dulaglutide 1.5 mg) of participants.

Side Effect Profile: What Actually Differs

Both drugs act on the GLP-1 receptor and share a GI side effect profile dominated by nausea, diarrhea, vomiting, and constipation. However, the magnitude differs meaningfully in clinical trials, while real-world severe event rates are comparable.

A 2025 network meta-analysis (Frontiers in Pharmacology, N = 27,729) confirmed dulaglutide has among the lowest nausea risk of all GLP-1 agonists (~10%), while semaglutide's nausea risk sits at ~21.5%. Semaglutide also showed higher vomiting risk (OR 1.75, 95% CI 1.15–2.66) and notably longer constipation duration (median 47 days on semaglutide vs 35 days on placebo in pooled STEP 1–4 analysis). The crucial counterpoint: a 2025 real-world cohort study (Annals of Internal Medicine) found no clinically meaningful difference in severe GI adverse events between semaglutide and dulaglutide in routine practice (HR 0.96, 95% CI 0.87–1.06). GI events peak during dose escalation and 99.5% are non-serious; most nausea episodes resolve within 8 days at a stable dose.

Cost as of June 2026

List prices for both agents remain high in the US, but manufacturer savings programs bring costs down substantially for commercially insured patients.

• Trulicity (dulaglutide): ~$987–$1,029/month list price. With the Eli Lilly savings card, commercially insured patients pay as little as $25/month; Lilly patient assistance covers full cost for qualifying uninsured patients. GoodRx cash: ~$965–$1,024 per 4-pen carton.
• Ozempic (semaglutide 0.5–2.0 mg, T2D): ~$1,027/month list price. NovoCare self-pay: $349/month. With Novo Nordisk savings card (commercially insured): as low as $25/fill, maximum $100/month savings.
• Wegovy (semaglutide 2.4 mg, weight management): ~$1,349/month list price. NovoCare self-pay: $349/month. Commercially insured: $0–$25/month with savings card. Starting July 1, 2026, the CMS Medicare GLP-1 Bridge demonstration covers Wegovy at a flat $50/month copay for eligible Part D beneficiaries (BMI ≥ 35, or BMI ≥ 30 with comorbidities).

Important 2027 change: On February 24, 2026, Novo Nordisk announced that effective January 1, 2027, the list price for Wegovy, Ozempic, and Rybelsus will be reduced to a unified $675/month — approximately 50% less than current Wegovy list pricing and 35% less for Ozempic. No equivalent reduction has been announced for Trulicity. Patients on commercial plans should also verify formulary coverage before switching: Ozempic is broadly covered for T2D, but Wegovy typically requires a separate prior authorization for the obesity indication.

When NOT to Switch

Not every patient on dulaglutide is a suitable candidate for semaglutide. Six scenarios warrant careful reconsideration:

• Prior or current gastroparesis. Semaglutide delays gastric emptying more potently than dulaglutide due to its higher receptor affinity and longer half-life. The FDA labels for both drugs note they are not recommended in patients with pre-existing gastroparesis. A 2023 JAMA pharmacoepidemiologic study found GLP-1 agonist users had a 3.67-fold higher risk of gastroparesis versus bupropion-naltrexone, specifically flagging semaglutide. A published case series documented a patient who tolerated maximum-dose dulaglutide for months but developed severe gastroparesis after just two semaglutide doses. Specialist evaluation is required before switching in any patient with confirmed or suspected gastroparesis.
• Prior severe intolerance to high-affinity GLP-1 agents. Dulaglutide has among the lowest nausea rates of all GLP-1 agonists. A patient tolerating it after failing earlier GLP-1 agents may be benefiting from its relatively mild receptor profile. These patients should re-titrate semaglutide at extended intervals (8-week holds at each dose rather than 4-week) with a clear stopping rule.
• Pregnancy planning. The FDA label for Ozempic/Wegovy recommends discontinuing semaglutide at least 2 months before a planned pregnancy (168h half-life × 5 = ~35 days, plus safety margin). Switching to semaglutide close to a planned conception date extends the required drug-free interval and may complicate preconception glycemic management.
• Personal or family history of medullary thyroid carcinoma (MTC) or MEN2. Semaglutide is absolutely contraindicated in these patients per FDA boxed warning. Importantly, so is dulaglutide — this scenario is most relevant when a patient with a missed MTC history is being evaluated for a switch and the contraindication is discovered at that point.
• Active or recent acute pancreatitis. The same 2023 JAMA study found a 9.09-fold higher risk of pancreatitis in GLP-1 users versus comparators. Switching GLP-1 agents in a patient with recent pancreatitis or known risk factors (gallstones, heavy alcohol use, hypertriglyceridemia) should be deferred until the pancreatic picture is stable and a specialist has evaluated the risk-benefit ratio.
• Well-controlled T2D with no weight-loss goal and favorable formulary access to Trulicity. A patient whose HbA1c is at goal on dulaglutide 1.5 mg, who is not pursuing additional weight loss, and who pays $25/month via the Lilly savings card has no compelling clinical reason to switch. Re-titration introduces GI effects, prior authorization burden, and potentially higher cost without metabolic benefit.